WM-115 - Cell Line (ID:50567)
| HMS LINCS ID: | 50567 |
| Name: | WM-115 |
| Alternative Names: | |
| LINCS ID: | LCL-1260 |
| Alternative ID: | CLO_0009613 |
| Parent Cell Line: | |
| Reference Source: | ATCC CRL-1675 |
| Organism: | Homo sapiens |
| Organ: | skin |
| Tissue: | |
| Cell Type: | |
| Details of Cell Type: | |
| Donor Sex: | female |
| Donor Age: | |
| Donor Ethnicity: | |
| Donor Health Status: | |
| Disease: | DOID:1909, malignant melanoma |
| Details of Disease: | |
| Production Details: | |
| Genetic Modification(s): | none |
| Known Mutations: | |
| Citation Information for Mutations: | COSS909784 |
| Verification Reference Profile: | |
| Growth Properties: | adherent |
| Recommended Culture Conditions: | From MGH/CMT as specified by cell provider: Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 90%; fetal bovine serum, 10%. Protocol: Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.03% EDTA solution to remove all traces of serum that contains trypsin inhibitor. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 34 to 35°C to facilitate dispersal. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new culture vessels. Incubate cultures at 34 to 35°C. Subcultivation ratio: A subcultivation ratio of 1:3 to 1:6 is recommended |
| Relevant Citations: | |
| Usage Note: | |
| Comments: | |
| Date Publicly Available: | 2012-07-31 |
| Most Recent Update: | 2016-04-04 |
Batch Information for HMSL50567-3:
| HMS LINCS Batch ID: | 50567-3 |
| Provider: | Nathan Moerke (Harvard Medical School) |
| Provider Catalog ID: | |
| Provider Batch ID: | |
| Source Information: | Obtained by Nathan Moerke (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes) and distributed to Mohammad Fallahi-Sichani in 2012 |
| Date Received: | 2012 |
| HMS QC Outcome: | |
| Transient Modification(s): | |
| Comments: | |
| Date Publicly Available: | 2016-12-22 |
| Most Recent Update: | 2016-12-22 |